Department of Health Economics, Corvinus University of Budapest, Hungary.
From the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University.
Dermatitis. 2022;33(6S):S92-S103. doi: 10.1097/DER.0000000000000908. Epub 2022 Jun 8.
Few studies have investigated health-related quality of life (HRQoL) in patients with atopic dermatitis (AD) during the COVID-19 pandemic.
The objectives of this study were to compare HRQoL in adult AD patients before and during the pandemic and to assess measurement performance of 4 HRQoL measures.
Between 2018 and 2021, a multicenter, cross-sectional survey was conducted, involving 218 adult AD patients. Health-related quality of life outcomes included the EQ-5D-5L, Skindex-16, Dermatology Life Quality Index (DLQI), and DLQI-Relevant (DLQI-R). Severity was measured using objective SCORing Atopic Dermatitis, Eczema Area and Severity Index, and Investigator Global Assessment.
The mean ± SD EQ-5D-5L utility, Skindex-16, DLQI, and DLQI-R scores were 0.82 ± 0.22, 56.84 ± 27.46, 13.44 ± 8.46, and 13.76 ± 8.60, respectively. The patients reported more problems during the pandemic ( P < 0.05) regarding pain/discomfort (odds ratio [OR], 1.78), worrying (OR, 1.89), concerns about persistence/reoccurrence of disease (OR, 1.88), and social relationships (OR, 1.69). The HRQoL outcomes showed strong correlations with each other (range of rs , |0.69| to |0.99|). The Skindex-16, DLQI, and DLQI-R were able to discriminate between severity groups with large (η 2 = 0.20-0.23), whereas the EQ-5D-5L with moderate effect sizes (η 2 = 0.08-0.11).
Atopic dermatitis patients experienced significantly more problems in some areas of HRQoL during the pandemic. The EQ-5D-5L, Skindex-16, DLQI, and DLQI-R demonstrated good convergent and known-group validity and can be suitable instruments for HRQoL assessment in clinical and research settings.
鲜有研究调查过 COVID-19 大流行期间特应性皮炎（AD）患者的健康相关生活质量（HRQoL）。
本研究旨在比较成人 AD 患者在大流行前后的 HRQoL，并评估 4 种 HRQoL 测量方法的测量性能。
2018 年至 2021 年间，进行了一项多中心、横断面调查，纳入了 218 例成年 AD 患者。HRQoL 结局包括 EQ-5D-5L、Skindex-16、皮肤病生活质量指数（DLQI）和 DLQI-相关（DLQI-R）。使用客观 SCORing 特应性皮炎、湿疹面积和严重程度指数和研究者全球评估来衡量严重程度。
平均 ± SD 的 EQ-5D-5L 效用、Skindex-16、DLQI 和 DLQI-R 评分分别为 0.82 ± 0.22、56.84 ± 27.46、13.44 ± 8.46 和 13.76 ± 8.60。患者在大流行期间报告了更多的问题（P<0.05），涉及疼痛/不适（优势比[OR]，1.78）、担忧（OR，1.89）、对疾病持续/复发的担忧（OR，1.88）和社会关系（OR，1.69）。HRQoL 结局彼此之间存在很强的相关性（rs 范围，|0.69|至|0.99|）。Skindex-16、DLQI 和 DLQI-R 能够区分严重程度组，差异具有较大效应量（η 2 = 0.20-0.23），而 EQ-5D-5L 的效应量中等（η 2 = 0.08-0.11）。
特应性皮炎患者在大流行期间经历了更多的 HRQoL 方面的问题。EQ-5D-5L、Skindex-16、DLQI 和 DLQI-R 表现出良好的收敛性和已知组有效性，可作为临床和研究环境中 HRQoL 评估的合适工具。
